Search Results
Your search for ,aLl matches 18306 pages
Showing 4601 - 4650International Medullary Thyroid Carcinoma Grading System: Detecting Adverse Outcomes
In a study reported in the Journal of Clinical Oncology, Xu et al developed a two-tiered international medullary thyroid carcinoma grading system that identifies high-grade disease associated with poorer outcomes. As stated by the investigators, “Currently, there is no widely accepted...
Optimizing Adjuvant Therapy for Women With Estrogen Receptor–Positive, Node-Positive Breast Cancer
“Nodal status remains the single most important prognostic marker in outcomes for women with estrogen receptor–positive, HER2-negative breast cancer. For that reason, it makes sense to think about optimizing adjuvant therapy, including endocrine treatments, chemotherapy, and targeted therapy,”...
Adjuvant Gefitinib vs Cisplatin/Vinorelbine for Completely Resected EGFR-Mutant Stage II to IIIA NSCLC
In the Japanese phase III IMPACT trial reported in the Journal of Clinical Oncology, Tada et al found that adjuvant gefitinib did not improve disease-free survival vs cisplatin/vinorelbine in patients with completely resected stage II to IIIA EGFR-mutant non–small cell lung cancer (NSCLC). In the...
Study Finds Lack of Health Insurance May Hinder Recommended Cancer Screening in Unemployed Adults
In a recent study published by Stacey Fedewa, PhD, and colleagues in the journal Cancer, unemployed individuals were less likely to have health insurance and be up to date on getting recommended cancer screening tests. Analyses revealed that their lack of health insurance coverage accounted for...
NSCLC in the United States: Update on Incidence, Prevalence, and Survival
In a study reported in JAMA Oncology, Apar Kishor Ganti, MD, MS, and colleagues found that the incidence of non–small cell lung cancer (NSCLC) has decreased in the United States in recent years. They also found that prevalence has increased, likely in association with more effective treatment and...
Ibrutinib Plus R-CHOP for Younger Patients With DLBCL
New evidence suggests that adding the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib to a standard chemotherapy regimen may improve survival among younger people with a specific form of diffuse large B-cell lymphoma (DLBCL). The findings, published by Wyndham Wilson, MD, PhD, in Cancer Cell,...
Study Finds Patients Infected With COVID-19 Who Underwent Recent Cancer Treatment Are at Higher Risk of Adverse Outcomes
In a cohort study reported in JAMA Oncology, Mariana Chavez-MacGregor, MD, MSc, and colleagues found that patients with cancer infected with COVID-19 had poorer outcomes vs patients without cancer if they had received recent cancer treatment. Patients with cancer who had not received recent...
Evidence for Efficacy of Sunitinib in Malignant Pheochromocytoma and Paraganglioma
Results from the phase II FIRSTMAPPP study support the potential use of the tyrosine kinase inhibitor sunitinib in two rare neuroendocrine malignancies—pheochromocytoma and paraganglioma. Sunitinib significantly improved the primary endpoint of progression-free survival vs placebo, according to...
Studies Find B7-H3 Protein May Be a Target for Prostate Cancer Treatment
The immune checkpoint protein B7-H3 may be a potential new target in treatment-resistant prostate cancers, according to two studies presented recently at the European Society for Medical Oncology (ESMO) Congress 2021. “Virtually every prostate cancer cell expresses some degree of B7-H3, which...
ESMO Women for Oncology Studies Examine Female Leadership in Oncology Over Time
Results of the European Society for Medical Oncology’s (ESMO) Women for Oncology monitoring and authorship studies were recently published by Berghoff et al in ESMO Open. They revealed that women continue to be underrepresented in leadership positions despite making up an increasing proportion of...
Retrospective Study Examines Real-World Survival in U.S. Women Treated for Early-Stage Breast Cancer
In a retrospective cohort study reported in JCO Oncology Practice, Gidwani et al found that among U.S. patients treated for early-stage breast cancer, those who were considered to be unrepresented in clinical trials have significantly poorer survival than those categorized as well represented....
Study Finds Younger B-Cell Non-Hodgkin Lymphoma Survivors May Have a Higher Risk of Age-Related Diseases Than Older Survivors
Non-Hodgkin lymphoma is one of the most common cancers diagnosed in the United States, accounting for nearly 4% of all cancers. This year, about 81,600 individuals will be diagnosed with non-Hodgkin lymphoma, and nearly 21,000 will die from the cancer. A study by Ocier et al published in Cancer...
Expert Point of View: Michaela A. Dinan, PhD
The invited discussant of the study on out-of-pocket costs of cancer care, Michaela A. Dinan, PhD, Co-Leader of Cancer Prevention and Control at Yale Cancer Center and Associate Professor of Chronic Disease Epidemiology at the Yale School of Public Health, Connecticut, underscored the study’s key...
Out-of-Pocket Costs on the Rise for the Four Most Common Cancers, Study Finds
Rising cost-sharing requirements from private insurance have exacerbated the financial burden for patients with cancer, according to research presented at the 2021 ASCO Quality Care Symposium.1 Analysis of claims data on the four most prevalent cancers in the United States—female breast,...
Addition of FDG-PET/CT and Staging Laparoscopy to the Initial Staging of Locally Advanced Gastric Cancer
In a Dutch cohort study (PLASTIC) reported in JAMA Surgery, Gertsen et al found that staging laparoscopy provided more diagnostic information resulting in change of treatment intent than F-18 fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT) in patients with...
Do Solid Organ Transplant Recipients With a Previous Cancer Diagnosis Have High Cure Probabilities?
In a study reported in the Journal of Clinical Oncology, Engels et al found that patients with a previous cancer diagnosis who underwent solid organ transplantation had high cancer cure probabilities. Additionally, posttransplantation cancer-specific survival was associated with cancer cure...
FDA Pipeline: Novel Treatments in Lymphoma, Nasopharyngeal Cancer, Solid Tumors, and More
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to agents for several kinds of lymphoma, as well as nasopharyngeal cancer; a Breakthrough Therapy designation for a treatment for patients with NTRK-positive advanced solid tumors; and Fast Track designation for...
Matthew Manning, MD, on Resolving Racial Disparities in the Treatment of Breast and Lung Cancers
Matthew Manning, MD, of Cone Health Cancer Center, discusses findings that showed changes to the way cancer care is delivered may help eliminate racial disparities in survival among patients with early-stage lung and breast cancers. Identifying and addressing obstacles that kept patients from...
Patient-Reported Outcomes in Gastrointestinal Cancers: Predicting Treatment Response and Survival Outcomes
According to data presented during the 2021 ASCO Quality Care Symposium,1 1-month changes in patient-reported outcomes may predict treatment response and survival outcomes in patients with advanced gastrointestinal cancers. The results of a prospective study of 159 patients with metastatic...
Primary Transoral Surgery and Reduced-Dose Adjuvant Radiation Therapy for HPV-Positive Locally Advanced Oropharyngeal Cancer
As reported in the Journal of Clinical Oncology by Robert L. Ferris, MD, PhD, and colleagues, the phase II ECOG-ACRIN E3311 trial has shown high progression-free survival rates and good functional outcomes in patients with intermediate-risk human papillomavirus (HPV; p16)-positive locally advanced...
Definitive Radiotherapy Without Systemic Therapy for Oligometastatic Renal Cell Carcinoma
In a single-center phase II study reported in The Lancet Oncology, Tang et al found that definitive radiotherapy in place of systemic therapy was feasible and effective for the treatment of oligometastatic renal cell carcinoma. As stated by the investigators, “The role of radiotherapy in metastatic ...
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children Aged 5 Through 11 Years
On October 29, the U.S. Food and Drug Administration (FDA) authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include children aged 5 through 11 years. The authorization was based on the FDA’s thorough and transparent evaluation of the data that...
Integrated Molecular-Morphologic Risk Predictor for Recurrence of Meningioma
In a study reported in the Journal of Clinical Oncology, Maas et al developed a novel integrated molecular-morphologic risk classification score that improved prediction of disease recurrence in patients with meningioma. Study Details The study involved DNA methylation, copy-number, and mutation...
First-Round Results of Prostate Cancer Screening for Men With Pathogenic Variants in Mismatch Repair Genes
As reported in The Lancet Oncology by Bancroft et al, the first round of prostate cancer screening in the IMPACT study of men with pathogenic variants in mismatch repair genes showed an increased risk of prostate cancer in carriers of MSH2 and MSH6 variants compared with noncarrier controls. As...
Patients With Multiple Myeloma May Lack T-Cell Responses to COVID-19 Vaccination
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccine may also fail to mount a T-cell response, according to research from the Icahn School of Medicine at Mount Sinai. Concerningly, this scenario was most common among patients actively treated with anti-CD38 and...
Hypofractionated Postoperative Prostate Bed Radiotherapy Does Not Increase Patient-Reported Toxicity for Men With Prostate Cancer
A primary endpoint analysis of the NRG Oncology phase III NRG-GU003 clinical trial, which compared hypofractionated postoperative prostate bed radiotherapy (HYPORT) to conventional postprostatectomy radiotherapy (COPORT) for men with prostate cancer, determined that treatment with HYPORT yielded no ...
Survey of U.S. Oncologists on Genetic Counseling and Testing for Black Women With Breast Cancer
As reported in the Journal of Clinical Oncology by Ademuyiwa et al, a survey of U.S. breast oncologists showed that physicians believe that Black women with breast cancer face more barriers to genetic counseling and testing compared to White women with breast cancer. Study Details The study...
Addition of Enasidenib to Azacitidine in Newly Diagnosed IDH2-Mutant Acute Myeloid Leukemia
As reported in The Lancet Oncology by Courtney D. DiNardo, MD, and colleagues, an interim analysis of the phase II portion of a phase Ib/II trial (AG221-AML-005) showed that the addition of the oral mutant IDH2 protein inhibitor enasidenib to azacitidine significantly improved overall response rate ...
Nivolumab for Relapsed Malignant Mesothelioma: Improvements in Progression-Free and Overall Survival
In the phase III CONFIRM trial reported in The Lancet Oncology, Dean A. Fennell, FRCP, PhD, and colleagues found that nivolumab improved progression-free and overall survival vs placebo in patients with relapsed malignant mesothelioma. In October 2020, the combination of nivolumab and ipilimumab...
Phase III Trial Evaluates Efficacy of Total Androgen Suppression Plus Dose-Escalated Radiotherapy for Patients With Intermediate-Risk Prostate Cancer
Both dose-escalated radiation therapy and short-course androgen-deprivation therapy (SADT) have been shown to improve outcomes in patients with intermediate-risk prostate cancer. Researchers then posed a new question—is giving both modalities upfront to newly diagnosed patients of benefit? Findings ...
Addition of Vincristine, Topotecan, and Cyclophosphamide to Five-Drug Interval-Compressed Chemotherapy for Ewing Sarcoma
As reported in the Journal of Clinical Oncology by Leavey et al, the phase III Children’s Oncology Group AEWS1031 trial showed no improvement in event-free or overall survival with the addition of vincristine, topotecan, and cyclophosphamide (VTC) to standard five-drug interval-compressed...
Expert Point of View: Pierre Laurent-Puig, MD
The invited discussant of the FOCUS4-C trial was Pierre Laurent-Puig, MD, Professor of Medicine, Université de Paris, Institut du Cancer Paris CARPEM. According to Dr. Laurent-Puig, the “promising results” for the WEE1 inhibitor adavosertib in colorectal cancer in the FOCUS4-C trial could apply to ...
FOCUS4-C Trial: Hint of Activity Reported With Adavosertib in Metastatic Colorectal Cancer
The novel WEE1 inhibitor adavosertib, given after induction chemotherapy, yielded a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with metastatic colorectal cancer and TP53/RAS mutations, according to the randomized phase II FOCUS4-C trial....
Baseline Health-Related Quality of Life and Outcomes in Patients With Advanced Cancer
In an analysis of SWOG clinical trials reported in JCO Oncology Practice, David Hui, MD, MS, MSc, and colleagues found that better baseline health-related quality of life was associated with better survival outcomes in patients with advanced cancer. Study Details The study involved a review of...
Annual Report to the Nation, Part 2: Focus on Patient Economic Burden Associated With Cancer Care
Part 2 of the latest Annual Report to the Nation on the Status of Cancer—provided by the American Cancer Society, National Cancer Institute, Centers for Disease Control and Prevention, and North American Association of Central Cancer Registries—has found that patients with cancer in the United...
Study Finds Prior Authorization Costs Academic Radiation Oncology Clinics More Than $40 Million Every Year
The time required to secure prior authorization approvals for radiation therapy equates to a financial impact of more than $40 million annually for academic medical centers, according to a new study presented by Bingham et al at the 2021 American Society for Radiation Oncology (ASTRO) Annual...
ACCURE Trial Aims to Eliminate Disparities in Survival in Black and White Patients With Early-Stage Lung and Breast Cancers
A study presented by Manning et al at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 53) showed that interventions to help Black patients overcome obstacles to completion of treatment can impact disparities in survival outcomes between Black and White patients...
Is Precision Oncology an Unsustainable Promise?
Despite the promise of precision oncology, the cost-effectiveness of targeted treatments remains open to debate. According to Aakash Desai, MD, MPH, there is an urgent need for drug-pricing reform, given the average expenditure of Medicare Part D. An analysis of the Medicare database presented...
22-Gene Classifier Score May Allow for Personalization of Therapy in Patients With High-Risk Prostate Cancer
A 22-gene genomic classifier (the Decipher score) may be able to predict the course of disease in men with high-risk prostate cancer, according to a patient-level meta-analysis of three randomized clinical trials presented by Paul L. Nguyen, MD, at the 2021 American Society for Radiation Oncology...
Is Cabozantinib Active in Treating Brain Metastases From Renal Cell Carcinoma?
In a retrospective cohort study reported in JAMA Oncology, Hirsch et al found that cabozantinib showed substantial activity in treating brain metastases in patients with renal cell carcinoma. As stated by the investigators, “Patients with brain metastases from renal cell carcinoma have been...
MD Anderson and Siemens Healthineers Collaborate to Enable Consistent Clinical Implementation of Quantitative MRI
The University of Texas MD Anderson Cancer Center and Siemens Healthineers recently announced the collaborative development of a global education program focused on enabling the implementation of consistent, high-quality magnetic resonance imaging (MRI) in radiation oncology. The program will...
Acupuncture vs Cognitive Behavioral Therapy for Cognitive Function in Cancer Survivors With Insomnia
Guest Editor’s Note: Cancer-related cognitive difficulties, experienced by many cancer survivors, include perceived or objective deficits in memory, attention, and concentration, which can negatively impact quality of life. Given the important role that healthful sleep plays in cognitive processes, ...
FDA Expands Cetuximab Label for Encorafenib Combination in BRAF V600E Mutation–Positive Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has granted approval of a new indication for the EGFR inhibitor cetuximab (Erbitux) in combination with encorafenib (Braftovi) for the treatment of adults with metastatic colorectal cancer and a BRAF V600E mutation, as detected by an FDA-approved test,...
Cardio-oncology
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
MD Anderson and BostonGene Announce Strategic Alliance to Advance Personalized Cancer Diagnostics and Treatments
The University of Texas MD Anderson Cancer Center and BostonGene Corporation recently announced a strategic alliance to advance the development and clinical integration of multiplatform biomarker signatures. Expands Upon Existing Collaborations The alliance brings together BostonGene’s innovative...
Urbanization in Bangladesh: The Prevalence of Breast Cancer Brings Unique Challenges
The number of deaths related to breast cancer are increasing at an alarming pace worldwide. According to a World Health Organization (WHO) 2020 report, approximately 2,088,849 new cases and 627,000 deaths related to breast cancer occurred in 2018.1 More than 55% of these deaths occurred in low- to ...
Extended Open Enrollment, Special Enrollment Periods Finalized for Some Insurance Exchanges, Increasing Access to Cancer Care
On September 17, 2021, the Centers for Medicare & Medicaid Services (CMS) finalized a rule that could increase access to cancer care through an extended open enrollment period and monthly special enrollment periods for federally facilitated health insurance exchanges and state-based exchanges...
Memorial Sloan Kettering Cancer Center Announces New Early-Career Physician Research Program in Cancer Science
Memorial Sloan Kettering Cancer Center (MSK) recently announced a $25 million gift from Louis V. Gerstner, Jr, to create the Louis V. Gerstner, Jr Physician Scholars Program. Designed to support the innovative research of physician-scientists who are early in their career at MSK, the program will...
Mobocertinib for Previously Treated Advanced NSCLC With EGFR Exon 20 Insertion Mutations
On September 15, 2021, the kinase inhibitor mobocertinib was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test,...
An Atypical Road to a Career in Medicine and Leading a Cancer Center for Robert A. Winn, MD
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Robert A. Winn, MD, Director of VCU Massey Cancer Center, Richmond, Virginia. In 2020, he became the first Black physician to lead a National Cancer Institute–designated cancer center. Among other...
